Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Banner naproxen petition

This article was originally published in The Tan Sheet

Executive Summary

FDA grants Banner Pharmacaps permission to file ANDA for naproxen sodium 220 mg capsules with same indication as Bayer's Aleve tablets but different dosage form. In Feb. 25 letter, agency finds "change in dosage form for the specific proposed drug product does not pose questions of safety or effectiveness because the uses, dose and route of administration...are the same as that of the listed drug product." However, FDA notes "approval of this petition to allow an ANDA to be submitted" does not necessarily mean ANDA will be approved. Banner submitted petition in November, has received approval for softgel version of Advil Liqui-Gels (1"The Tan Sheet" Nov. 18, 2002, In Brief)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095232

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel